Citation Impact
Citing Papers
NSAID use and dementia risk in the Cardiovascular Health Study*
2007
Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ
2006
NOTCH Signaling Is Required for Formation and Self-Renewal of Tumor-Initiating Cells and for Repression of Secretory Cell Differentiation in Colon Cancer
2010 StandoutNobel
Interactions between APP secretases and inflammatory mediators
2008
Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice
2005
In situ click chemistry generation of cyclooxygenase-2 inhibitors
2017 Standout
Pharmacological strategies for the regulation of inducible nitric oxide synthase: Neurodegenerative versus neuroprotective mechanisms
2006
Microglia as a Potential Bridge between the Amyloid β‐Peptide and Tau
2004
Transgenic mouse models of Alzheimer's disease: How useful have they been for therapeutic development?
2004
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
2004 Standout
A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model
2005
Inflammatory processes in Alzheimer's disease
2007
Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity
2003
3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate β-Amyloid-Induced Microglial Inflammatory Responses
2005
Is there a future for vaccination as a treatment for Alzheimer's disease?
2003
Systemic infections and inflammation affect chronic neurodegeneration
2007
Different pathways for iNOS‐mediated toxicity in vitro dependent on neuronal maturation and NMDA receptor expression
2002
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
Ibuprofen-like activity in extra-virgin olive oil
2005 StandoutNature
Age-Related Macular Degeneration
2008 Standout
Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice
2002
Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
2001
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
2002
The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (`ecstasy')
1998
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
2012 Standout
Foundation models for generalist medical artificial intelligence
2023 StandoutNature
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
2007 Standout
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
2006
Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease
2003
3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans
1999
Alzheimer's disease
2011 Standout
A century-old debate on protein aggregation and neurodegeneration enters the clinic
2006 Nature
Exchange of N-CoR Corepressor and Tip60 Coactivator Complexes Links Gene Expression by NF-κB and β-Amyloid Precursor Protein
2002
PGH2‐derived levuglandin adducts increase the neurotoxicity of amyloid β1–42
2006
Effective gene expression prediction from sequence by integrating long-range interactions
2021 StandoutNobel
Balancing Acts
2004 Standout
Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (‘Ecstasy’)
2000
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
2001 Nature
Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4‐methylenedioxymethamphetamine (‘ecstasy’)‐induced dopamine release and free radical formation in the mouse striatum
2002
3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose
2001
The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κB Kinase, and NFκB, Do Not Reduce Amyloid β42 Production
2003
IL-10 Alters Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive Behavior
2015
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
2003 Standout
Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
2001
Modulation of Nuclear Factor-κB Activity by Indomethacin Influences Aβ Levels but Not Aβ Precursor Protein Metabolism in a Model of Alzheimer's Disease
2004
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Multiple sclerosis
2008 Standout
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
2012 StandoutNature
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
2015 Standout
Microglial Activation is Required for Aβ Clearance After Intracranial Injection of Lipopolysaccharide in APP Transgenic Mice
2007
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
2019 Standout
Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo
2004 Standout
Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”)
1995
The Role of Insulin Resistance in the Pathogenesis of Alzheimer??s Disease
2003
In vivo evidence for free radical involvement in the degeneration of rat brain 5‐HT following administration of MDMA (‘ecstasy’) and p‐chloroamphetamine but not the degeneration following fenfluramine
1997
Neurodegeneration and Inflammation
2008
Aplastic anaemia following exposure to 3,4‐methylenedioxymethamphetamine (‘Ecstasy’)
1994
Dissection of Amyloid-β Precursor Protein-dependent Transcriptional Transactivation
2004 StandoutNobel
Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease
2008
Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) are Attenuated by the Serotonin Uptake Inhibitor Citalopram
2000
Chronic nicotine treatment reduces β‐amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw)
2002
The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype
1995
Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology
2007
Acute Toxicity of 3,4-Methylenedioxymethamphetamine (MDMA) in Sprague–Dawley and Dark Agouti Rats
1999
Deletion of the Prostaglandin E2EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease
2005
Nuclear receptor peroxisome proliferator‐activated receptor‐γ is activated in rat microglial cells by the anti‐inflammatory drug HCT1026, a derivative of flurbiprofen
2005
From endoplasmic-reticulum stress to the inflammatory response
2008 StandoutNature
Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice
2001
3,4-Methylenedioxymethamphetamine (“Ecstasy”) Stimulates the Expression of α1(I) Procollagen mRNA in Hepatic Stellate Cells
1999
Alzheimer's disease
2006 Standout
Absence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease
2004
Anti-Aβ Drug Screening Platform Using Human iPS Cell-Derived Neurons for the Treatment of Alzheimer's Disease
2011 StandoutNobel
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>
2009
Inflammatory Neurodegeneration Mediated by Nitric Oxide, Glutamate, and Mitochondria
2003
Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia
2001
Alzheimer's Disease
2010 Standout
Does my mouse have Alzheimer's disease?
2002
Towards a comprehensive catalogue of validated and target-linked human enhancers
2020
LTP and LTD
2004 Standout
The impact of systemic infection on the progression of neurodegenerative disease
2003
Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target γ-Secretase at a Novel Site
2004
Mechanisms and Functions of Inflammasomes
2014 Standout
Negative Regulation of Hypoxic Responses via Induced Reptin Methylation
2010 StandoutNobel
Tannic Acid Is a Natural β-Secretase Inhibitor That Prevents Cognitive Impairment and Mitigates Alzheimer-like Pathology in Transgenic Mice
2012
Lack of Specific Amyloid-β(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures
2004
Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors
1997
Role of Free Radicals in the Neurodegenerative Diseases
2001 Standout
Systematic Mutagenesis of α-Synuclein Reveals Distinct Sequence Requirements for Physiological and Pathological Activities
2012 StandoutNobel
Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the dark agouti rat
2004
Sulindac Sulfide Is a Noncompetitive γ-Secretase Inhibitor That Preferentially Reduces Aβ42 Generation
2003
Microglial EP2 as a New Target to Increase Amyloid β Phagocytosis and Decrease Amyloid β-Induced Damage to Neurons
2006
Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice
2005
Alzheimer's Disease
2004 Standout
Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease
2005
Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics
2005
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human β-amyloid
2005
From inflammation to sickness and depression: when the immune system subjugates the brain
2007 Standout
Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies
2001
A role for local inflammation in the formation of drusen in the aging eye
2002
The role of microglia in amyloid clearance from the AD brain
2010
Antibodies against β‐amyloid reduce aβ oligomers, glycogen synthase kinase‐3β activation and τ phosphorylation in vivo and in vitro
2005
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
2017 Standout
Aminopyridazines inhibit β-amyloid-induced glial activation and neuronal damage in vivo
2004
Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy)
1999
Pathways towards and away from Alzheimer's disease
2004 StandoutNature
Molecular Mechanisms of Amyloidosis
2003 Standout
Overexpression of Monocyte Chemotactic Protein-1/CCL2 in β-Amyloid Precursor Protein Transgenic Mice Show Accelerated Diffuse β-Amyloid Deposition
2005
Peripheral Treatment with Enoxaparin, a Low Molecular Weight Heparin, Reduces Plaques and β-Amyloid Accumulation in a Mouse Model of Alzheimer's Disease
2004
Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP
2010 StandoutNobel
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
2003
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
2017 Standout
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
2005 Standout
Long-Term Potentiation and Memory
2004
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
2012
EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity
2010 Standout
Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model
2008 StandoutNobel
Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications
2019 Standout
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
2002 StandoutScience
One-Step Assembly of Coordination Complexes for Versatile Film and Particle Engineering
2013 StandoutScience
Extending the Nested Model for User-Centric XAI: A Design Study on GNN-based Drug Repurposing
2022
Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases and Amyotrophic Lateral Sclerosis)
2006 Standout
Binding of F-spondin to amyloid-β precursor protein: A candidate amyloid-β precursor protein ligand that modulates amyloid-β precursor protein cleavage
2004 StandoutNobel
The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse
2001
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
2001 StandoutScience
β-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or β-amyloid deposits
2006
Reduction of amyloid load and cerebral damage in transgenic mouse model of Alzheimer's disease by treatment with a β‐sheet breaker peptide
2002
Reduced incidence of AD with NSAID but not H2receptor antagonists
2002
Modulation of β‐amyloid metabolism by non‐steroidal anti‐inflammatory drugs in neuronal cell cultures
2003
Supramolecular Helical Systems: Helical Assemblies of Small Molecules, Foldamers, and Polymers with Chiral Amplification and Their Functions
2016 Standout
The microglial phagocytic role with specific plaque types in the Alzheimer disease brain
2004
Non‐linear pharmacokinetics of MDMA (‘ecstasy’) in humans
2000
Reduction of Aβ accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidylinositol kinase inhibitor wortmannin
2000
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
2003
Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease
2003
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
Microglial Activation and β-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice
2002
Pathology of deaths associated with "ecstasy" and "eve" misuse.
1996
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
2003
Stereospecific Analysis and Enantiomeric Disposition of 3,4-Methylenedioxymethamphetamine (Ecstasy) in Humans
1999
Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine (“ecstasy”): is metabolism a contributory factor?
2001
Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation
2004
Cleavage of Amyloid-β Precursor Protein and Amyloid-β Precursor-like Protein by BACE 1
2004 StandoutNobel
Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß 42 by Inhibiting Rho
2003 Science
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia
2006 Standout
Works of Tinyi Chu being referenced
Dynamic evolution of regulatory element ensembles in primate CD4+ T cells
2018
The demethylenation of methylenedioxymethamphetamine (“ecstasy”) by debrisoquine hydroxylase (CYP2D6)
1994
Selective inhibition of Aβ42 production by NSAID R‐enantiomers
2002
Transcriptional response to stress is pre-wired by promoter and enhancer architecture
2017
Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease
2000